Analysts at Stifel Nicolaus began coverage on shares of Candel Therapeutics (NASDAQ:CADL – Get Free Report) in a report released on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $22.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 131.82% from the stock’s current price.
Several other analysts have also commented on the company. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 1st. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Finally, Cantor Fitzgerald initiated coverage on Candel Therapeutics in a research note on Monday, April 20th. They set an “overweight” rating on the stock. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Candel Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.57.
View Our Latest Stock Analysis on CADL
Candel Therapeutics Price Performance
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. Research analysts predict that Candel Therapeutics will post -0.97 earnings per share for the current fiscal year.
Insider Transactions at Candel Therapeutics
In other news, insider Francesca Barone sold 23,447 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. This represents a 23.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the transaction, the chief technology officer owned 83,865 shares in the company, valued at $840,327.30. This trade represents a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Candel Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets increased its stake in shares of Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Candel Therapeutics in the fourth quarter valued at approximately $51,000. Tower Research Capital LLC TRC increased its position in shares of Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after purchasing an additional 7,527 shares in the last quarter. Invesco Ltd. acquired a new position in Candel Therapeutics in the 1st quarter valued at $59,000. Finally, ProShare Advisors LLC purchased a new position in Candel Therapeutics in the 4th quarter valued at $59,000. 13.93% of the stock is owned by hedge funds and other institutional investors.
Candel Therapeutics Company Profile
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- 3 Non-Tech Stocks Still Winning Big on AI
- Achieve Robust Diversification With These 3 Equal-Weight ETFs
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
